← Back to Screener
Iterum Therapeutics plc Ordinary Share (ITRM)
Price$0.03
Favorite Metrics
Price vs S&P 500 (26W)-104.70%
Price vs S&P 500 (4W)-90.89%
Market Capitalization$1.15M
All Metrics
Book Value / Share (Quarterly)$0.26
P/TBV (Annual)0.39x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-95.18%
Net Profit Margin (TTM)-2302.31%
EPS (TTM)$-0.75
10-Day Avg Trading Volume1.20M
EPS Excl Extra (TTM)$-0.75
EPS (Annual)$-1.25
ROI (Annual)-78.68%
Net Profit Margin (5Y Avg)-40639.07%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-55.56%
EBITD / Share (TTM)$-0.55
ROE (5Y Avg)-116.44%
Operating Margin (TTM)-1982.31%
Cash Flow / Share (Annual)$-0.84
P/B Ratio0.34x
P/B Ratio (Quarterly)2.92x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)61.24x
Net Interest Coverage (TTM)-0.37x
ROA (TTM)-74.63%
EPS Incl Extra (Annual)$-1.25
Current Ratio (Annual)1.39x
Quick Ratio (Quarterly)1.80x
3-Month Avg Trading Volume11.56M
52-Week Price Return-97.14%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.23
P/S Ratio (Annual)28.78x
Asset Turnover (Annual)0.00x
52-Week High$1.42
Operating Margin (5Y Avg)-31510.38%
EPS Excl Extra (Annual)$-1.25
CapEx CAGR (5Y)-36.90%
Tangible BV CAGR (5Y)-7.85%
26-Week Price Return-95.96%
Quick Ratio (Annual)1.36x
13-Week Price Return-90.80%
Total Debt / Equity (Annual)1.02x
Current Ratio (Quarterly)2.13x
Enterprise Value$23.884
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-45.24%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-256725.00%
Cash / Share (Annual)$0.75
3-Month Return Std Dev401.72%
Net Income / Employee (TTM)$-3
ROE (Last FY)-158.68%
Net Interest Coverage (Annual)-3.44x
EPS Basic Excl Extra (Annual)$-1.25
Total Debt / Equity (Quarterly)5.76x
EPS Incl Extra (TTM)$-0.75
ROI (TTM)-74.22%
P/S Ratio (TTM)2.95x
Pretax Margin (5Y Avg)-40344.92%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.09
Price vs S&P 500 (52W)-132.24%
Year-to-Date Return-91.04%
5-Day Price Return87.50%
EPS Normalized (Annual)$-1.25
ROA (5Y Avg)-105.37%
Net Profit Margin (Annual)-257825.00%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-2.30
EBITD / Share (Annual)$-1.25
Operating Margin (Annual)-255050.00%
LT Debt / Equity (Annual)1.02x
ROI (5Y Avg)-84.30%
LT Debt / Equity (Quarterly)5.76x
EPS Basic Excl Extra (TTM)$-0.75
P/TBV (Quarterly)3.30x
P/B Ratio (Annual)0.37x
Pretax Margin (TTM)-2268.46%
Book Value / Share (Annual)$2.22
Price vs S&P 500 (13W)-93.66%
Beta3.35x
Revenue / Share (TTM)$0.01
ROE (TTM)-216.35%
52-Week Low$0.01
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ITRMIterum Therapeutics plc Ordinary Share | 2.95x | — | — | — | $0.03 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Iterum Therapeutics is a pharmaceutical company commercializing Orlynvah, an oral-branded penem antibiotic approved in the United States for treating complicated urinary tract infections. Orlynvah has the potential to be the first and only oral and intravenous branded penem available globally. The company targets drug-resistant bacterial infections, addressing a significant unmet medical need.